Rigosertib clinical trial
The EB House Austria in Salzburg initiated a clinical trial, testing efficacy and safety of Rigosertib for RDEB patients with squamous cell carcinoma (PI: Univ.Prof. Dr. Johann Bauer, MBA). The work is funded by DEBRA International (lead applicant: Assoc.Prof. Dr. Andrew South). The trial site in Salzburg is the first centre open for patient recruitment; a second site in London will be opened in autumn.
You can find further information on the website www.clinicaltrials.gov